Instrumento Inactivo

Acciones Tobira Therapeutics Inc Nasdaq

Acciones

Duración

Período

Estilo

TOBIRA fait gagner plus de 40 000 euros à un investisseur !	26/10/16
Tobira Therapeutics : Announces Late-Breaking Oral Presentation of CENTAUR Phase 2b Trial Results at the American Academy for the Study of Liver Diseases Annual Meeting	20/10/16
Tobira Therapeutics : Announces Presentations Related to Cenicriviroc’s Development Program in NASH at the American Academy for the Study of Liver Diseases Annual Meeting	03/10/16
TBRA Brower Piven Commences An Investigation Into The Proposed Sale Of Tobira Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	21/09/16
Tobira Therapeutics : Allergan to Acquire Tobira Therapeutics Expanding Global GI R&D Pipeline and Taking a Leading R&D Position in NASH	20/09/16

Directores	Puesto	Edad	Desde
Robert Michael CEO	Chief Executive Officer	53	-
Scott Reents DFI	Director of Finance/CFO	57	-
Jennifer M. Lagunas SEC	Corporate Secretary	-	-

Sector

	Varia. 1 de ene.	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+9,42 %	115 mil M
REGENERON PHARMACEUTICALS, INC.	+11,84 %	106 mil M
ARGENX SE	-1,05 %	21,96 mil M
BIONTECH SE	-14,15 %	21,84 mil M
GENMAB A/S	-5,29 %	19,21 mil M
BEIGENE, LTD.	-4,16 %	18,08 mil M
WUXI APPTEC CO., LTD.	-38,29 %	17,71 mil M
NEUROCRINE BIOSCIENCES, INC.	+7,99 %	14,32 mil M
SAREPTA THERAPEUTICS, INC.	+36,24 %	12,42 mil M